PURCHASE, N.Y. -- In an effort to help the victims of SARS in Hong Kong maintain a healthy immune response, Quality of Life Labs, Inc., has made arrangements with the Hong Kong Ministry of Health to ship 300 bottles ($30,000 value) of ImmunoKinoko AHCC to assist in their efforts. Additional ImmunoKinoko will be provided over the upcoming months.
ImmunoKinoko AHCC contains Active Hexose Correlated Compound, a Japanese medicinal mushroom extract used to strengthen the immune system. The ingredient is derived from a highly specialized manufacturing process developed in the mid-1980s that relies on the hybridization of several species of mushrooms cultivated in Japan.
While no one knows what causes SARS yet, it is clear that the vast majority of diseases we come into contact with on a daily basis can be managed by the body s immune system, stated Fred Pescatore, MD, MPH and medical director of the AHCC Research Association. By providing some of those who are suffering with ImmunoKinoko AHCC, we hope we can help them remain healthy until a cure is discovered for this mysterious flu-like illness. Also, we would like to alert the public how important it is to strengthen the immune system during times of crises.
To date, more than 2,630 cases and 95 deaths have been reported in 17 countries in Asia, Europe and North America since mid-November, when SARS emerged in China.
ImmunoKinoko AHCC is packaged in bottles of 60 capsules, 500 mg each, with a suggested daily use of two to six capsules daily. According to industry analysts in Japan, more than 700 hospitals and medical clinics currently recommend AHCC to patients in that country as part of an immune support regimen.
Quality of Life Labs, sister company to Maypro Industries, Inc. located in Purchase, N.Y., is the sole U.S. distributor of AHCC.
Ensuring Safety and Comfort: The Urgent Need for Well-Fitted PPE in Health Care
April 5th 2024Personal protective equipment (PPE) stands as the first line of defense against infectious diseases in health care. Yet, the issue of ill-fitting PPE, especially for women, remains a significant challenge.
COVID-19 Harmonization: Balancing Risks and Benefits of CDC's Latest Move
March 11th 2024The CDC's recent decision to align recommendations for respiratory viruses, particularly COVID-19, has garnered support from the public and infectious disease societies. However, as the Infectious Diseases Society of America (IDSA) lends its backing to the CDC's harmonization efforts, concerns persist regarding the implications of this shift, especially considering the Omicron variant's unique characteristics and the ongoing challenges posed by COVID-19's multi-system impacts.
Voices of Resilience: Q&A With the Editor of "Corona City: Voices From an Epicenter"
March 1st 2024Step into the diverse and poignant world of "Corona City: Voices From an Epicenter" with editor Lorraine Ash, MA. In this insightful Q&A, learn about the origins of this remarkable anthology, the challenges faced in capturing raw, unfiltered narratives of the COVID-19 pandemic, and the lasting impact of these stories on readers and communities alike.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.